News for Patients and Caregivers
- This topic has 0 replies, 1 voice, and was last updated 5 years, 5 months ago by
.
-
Posts
-
Thanks to Mary for compiling this info.
News for Patients and Caregivers
The 2018 Congress of the European Society for Medical Oncology is meeting this week, and pharmaceutical companies working on new cancer treatments are presenting their progress. There is much good news to report for cholangiocarcinoma patients and caregivers. For example, an analogue of gemcitabine (“Acelarin”), two new treatments for cholangiocarcinoma patients with the FGFR mutation, and two new treatments for patients with TRK mutations all show promising results in clinical trials. I would like to take this opportunity to express appreciation to cholangiocarcinoma patients and their caregivers who, with courage and commitment, have participated in these and other clinical trials that benefit our community.
Links to press releases appear below.
Acelarin (NuCana): “In this Phase Ib multi-center, open-label study in front-line treatment of patients with advanced biliary tract cancer, Acelarin combined with cisplatin was observed to continue to achieve approximately a doubling of the response rate expected with the standard of care, gemcitabine plus cisplatin.”
http://www.nucana.com/downloads/NuCana21October2018.pdf
Infigratinib, formerly BGJ398 (QED Therapeutics): “These results show that infigratinib has strong potential to make a real difference in the lives of people with cholangiocarcinoma,” said Susan Moran, M.D., M.S.C.E., chief medical officer of QED Therapeutics. “Importantly, we have initiated a pivotal, Phase 3 study in first-line cholangiocarcinoma in the hopes of offering patients an upfront chemotherapy-free treatment option.”
Pemigatinib, formerly INCB54828 (Incyte Corporation): “In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint.”
Entrectinib (Roche): “ ‘These data demonstrate the potential of entrectinib to treat a range of difficult-to-treat and rare cancers regardless of their site of origin,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development.'”
https://www.roche.com/investors/updates/inv-update-2018-10-21.htm
Larotrectinib (Loxo Oncology): “‘It is exciting to see larotrectinib deliver durable responses to patients in these studies with TRK fusion cancer, regardless of age, tumor site of origin, or CNS involvement,’ said Ulrik Lassen, M.D., Ph.D., Department of Oncology, Rigshospitalet, Copenhagen.”
Thanks to Mary for this and to all of the companies and organisations listed and linked to above.
Gavin
- The forum ‘Chemotherapy & More’ is closed to new topics and replies.